The only patient in the cohort with loss of PBRM1 (poly bromo-1) expression showed a distinct profile...As shown here, clinical data suggest that negative expression of PBRM1 is correlated with advanced tumor stage, low differentiation grade, and worse patient outcome...We found that an angiogenic phenotype defined by a high vascular density with a vascular type 2 stroma was a predictive factor of sunitinib resistance. Regardless of adjuvant treatment, chromosomal gains and losses and genomic alterations including PBRM1 loss were associated with worse outcomes.